ePrints

Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target

Lookup NU author(s): Professor Ruth Plummer

Downloads

• Published version [.pdf]

Abstract

Inhibitors of various elements of the DNA repair pathways have entered clinical development or are in late preclinical stages of drug development. It was initially considered that agents targeting DNA repair would act to overcome tumor resistance to chemotherapy and radiotherapy. More recent data have shown that targeting DNA repair pathways can be effective in selected tumors via a synthetically lethal route, with single agent activity having been shown with poly-ADP ribose polymerase (PARP) inhibitors. An increased understanding of the biology and interaction of the DNA repair pathways also means that rational combination of DNA repair inhibitors may also give great benefit in the clinic. Clin Cancer Res; 16(18); 4527-31. (c) 2010 AACR.

Publication metadata

Author(s): Plummer R

Publication type: Article

Publication status: Published

Journal: Clinical Cancer Research

Year: 2010

Volume: 16

Issue: 18

Pages: 4527-4531

Print publication date: 07/09/2010

Date deposited: 14/01/2011

ISSN (print): 1078-0432

ISSN (electronic): 1557-3265

Publisher: American Association for Cancer Research

URL: http://dx.doi.org/10.1158/1078-0432.CCR-10-0984

DOI: 10.1158/1078-0432.CCR-10-0984

Altmetrics

Funding

Share